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Background: Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC)
according to menopausal status needs a biological explanation.
Methods: We compared early-stage HR+ BC biological features before and after (neo)adjuvant chemotherapy
or endocrine therapy (ET), and assessed oestrogen receptor (ER) pathway activity in both pre- and post-men-
opausal patients. The nCounter platform was used to detect gene expression levels.
Findings: In 106 post-menopausal patients with HR+/HER2-negative BC randomized to neoadjuvant chemo-
therapy or ET (letrozole+ribociclib), a total of 19 oestrogen-regulated genes, including progesterone receptor
(PGR), were found downregulated in the ET-based arm-only. We confirmed this finding in an independent
dataset of 20 letrozole-treated post-menopausal patients and found, conversely, an up-regulation of the
same signature in HR+/HER2-negative MCF7 cell line treated with estradiol. PGR was found down-regulated
by 2 weeks of ET+anti-HER2 therapy in pre-/post-menopausal patients with HR+/HER2-positive (HER2+) BC,
while anti-HER2 therapy alone increased PGR expression in HR-negative/HER2+ BC. In 88 pre- and post-men-
opausal patients with newly diagnosed HR+/HER2-negative BC treated with chemotherapy, the 19 oestro-
gen-regulated genes were found significantly downregulated only in pre-menopausal patients. In
progesterone receptor (PR)+/HER2-negative BC treated with neoadjuvant chemotherapy (n=40), tumours
became PR-negative in 69.2% of pre-menopausal patients and 14.8% of post-menopausal patients (p=0.001).
Finally, a mean decrease in PGR levels was only observed in pre-menopausal patients undergoing anti-HER2-
based multi-agent chemotherapy.
Interpretation: Chemotherapy reduces the expression of ER-regulated genes in pre-menopausal women suf-
fering from hormone-dependent BC by supressing ovarian function. Further studies should test the value of
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Hormone receptor-positive (HR+) breast cancer is a major cause of
cancer death [1]. Early-stage treatment consists of loco-regional ther-
apy and adjuvant endocrine therapy [2]. (Neo)adjuvant chemother-
apy is generally indicated for patients with high-risk HR+ tumours
that usually have a high-proliferative state, which is a general bio-
marker of chemotherapy responsiveness [3,4]. In HR+ breast tumours
with low-to-intermediate proliferation, however, recent results from
three large, randomized adjuvant clinical trials (i.e., TailorX [3],
MINDACT [4] and RxPONDER [5]) suggest that chemotherapy
improves survival outcomes in pre-menopausal patients yet not in
those who are post-menopausal. The biological explanation behind
this observation remains unknown. On one hand, intrinsic genomic
features of tumour cells in young women might render tumour cells
more sensitive to chemotherapy [6]. On the other hand, chemother-
apy’s ability to induce ovarian failure or premature menopause is
well-established [7]; hence, this could lead to a decrease of systemic
levels of oestrogen [710]. To optimize the treatment landscape of early-
stage HR+ breast cancer, a better understanding of this clinical observa-
tion is needed because these alternative hypotheses couldmean different
treatment options for youngwomenwith breast cancer.
2. Methods
To address the potential anti-oestrogen effects of chemotherapy
in breast cancer, we analyzed tumour samples from 4 clinical trials, 2
retrospective cohorts from the Hospital Clinic of Barcelona (HCB) and
a publicly available cell line-derived dataset, as subsequently
described.
Patient cohorts. The SOLTI-1402 CORALLEEN trial is an open-label,
phase II parallel, two-arm, neoadjuvant trial, where 106 post-meno-
pausal patients with stage I-IIIA HR+/HER2- negative and luminal B
(by the standardized PAM50/Prosigna assay) breast cancer were
randomized 1:1 to receive either six cycles of 28 days of oral riboci-
clib 600mg once daily on a 3 weeks-on 1week-off schedule plus con-
tinuous letrozole 2.5 mg once daily or standard neoadjuvant
chemotherapy with four cycles of doxorubicin 60mg/m2 and cyclo-
phosphamide 600mg/m2 intravenous (IV) every 21 days followed by
paclitaxel 80mg/m2 during 12 weeks. Tumour samples were col-
lected at baseline and at surgery, and subsequently formalin-fixed
paraffin-embedded (FFPE) according to protocol. The main results of
the SOLTI-CORALLEEN trial have been previously reported [11]. This
study is registered in ClinicalTrials.gov with number NCT03248427
and is completed.
SOLTI-1501 VENTANA trial is a neoadjuvant phase II trial that ran-
domized a total of 61 post-menopausal patients diagnosed with stage
I-IIIA HR+/HER2-negative breast to receive either letrozole 2.5 mg
daily, oral metronomic vinorelbine 50 mg 3 days a week or letrozole
2.5 mg daily and oral metronomic vinorelbine 50 mg three times a
week for 3 weeks. Tumour samples were collected at baseline and
after 3 weeks of letrozole treatment and subsequently FFPE according
to protocol. The main results of the SOLTI-1501 VENTANA have been
previously reported [12]. This study is registered in ClinicalTrials.gov
with number NCT02802748 and is completed.
The PAMELA trial is a non-randomized, open label, multicentric
phase II study of neoadjuvant dual HER2 blockade therapy withoutchemotherapy, where 151 patients with early HER2+ breast cancer
were treated with neoadjuvant lapatinib (1,000 mg daily) and trastu-
zumab (8 mg/kg i.v. loading dose followed by 6 mg/kg) for 18 weeks.
Patients with HR+ breast cancer received letrozole or tamoxifen
according to menopausal status. The main results of the PAMELA trial
have been previously reported [13]. Tumour samples were collected
at baseline, day 14 and surgery and subsequently formalin-fixed par-
affin-embedded (FFPE) according to protocol. This study is registered
in ClinicalTrials.gov with number NCT01973660 and is completed.
SOLTI-1007 NEOERIBULIN trial is a neoadjuvant phase II, single-
arm trial that included 174 stage II-III HER2-negative breast cancer
patients (73 triple-negative and 101 HR+/HER2-negative) to receive
1.4 mg/m2 of eribulin intravenously on days 1 and 8 every 21-day
cycle, for 4 cycles. Tumour samples were collected at baseline and at
surgery and subsequently FFPE according to protocol. The main
results of the SOLTI-1007 NEOERIBULIN study have been previously
reported [14]. This study is registered in ClinicalTrials.gov with num-
ber NCT01669252 and is completed.
Hospital Clinic HR+/HER2-negative neoadjuvant cohort is a retro-
spective cohort of 40 patients diagnosed with stage II-III HR+/HER2-
negative breast cancer (13 pre-menopausal and 27 post- meno-
pausal), between 2015-2018 at the HCB. All patients received an
anthracycline/taxane-based neoadjuvant chemotherapy. Tumour
samples were collected at baseline and surgery and subsequently
FFPE.
Hospital Clinic HER2+ neoadjuvant cohort is a retrospective
cohort of 73 pre-menopausal and post-menopausal patients diag-
nosed with HER2+ early stage (II/III) breast treated with neoadjuvant
anti-HER2-based multi-agent chemotherapy between 2008 and 2017
at the HCB. FFPE tumour samples were collected at baseline and sur-
gery (if residual disease).
2.1. Ethics
Each study was conducted according to the Declaration of Hel-
sinki. For each one of the previously mentioned patient cohorts, an
informed consent for study participation had been previously
obtained from all patients enrolled in each individual study. HCB
cohorts included patients in observational studies for which Ethic
approval was granted by the ethics committee of the HCB (IRB: HCB/
2021/0007 and HCB/2015/0491). All other cohorts proceeded from
clinical trials that were approved by independent ethics committees
at each centre, as specified in the respective publications.
RNA extraction. RNA was extracted from formalin-fixed paraffin-
embedded tumour samples from the HCB neoadjuvant HER2+ cohort,
the SOLTI-CORALLEEN, SOLTI-VENTANA, PAMELA and SOLTI-NEOERI-
BULIN trials using the High Pure FFPET RNA isolation kit (Roche, Indi-
anapolis, IN, USA). At least 15 10 mm FFPE slides were used for each
tumour specimen, and macrodissection was performed to avoid con-
tamination with normal breast tissue, if needed. RNA was quantified
at the NanoDrop spectrophotometer (Thermo Fisher Scientific, Wal-
tham, MA, USA).
Gene expression analysis. A minimum of 100 ng of total RNA was
used to measure gene expression across the SOLTI-CORALLEEN,
SOLTI-VENTANA, PAMELA and SOLTI- NEOERIBULIN trials and 1 neo-
adjuvant cohort of the HCB using the nCounter platform (NanoString
Technologies, Seattle, Washington, USA). In SOLTI-CORALLEEN and
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which includes 771 breast cancer-related genes. In PAMELA, a custom
made codeset of 560 breast cancer-related genes was used. In SOLTI-
NEOERIBULIN, a custom made codeset of 540 breast cancer-related
genes was used. In the neoadjuvant cohort of the HCB, a custom
made codeset of 60 genes was used. Across the 5 studies, genomic
data were normalized using 5 housekeeping genes (ACTB, MRPL19,
PSMC4, RPLP0 and SF3A1) and log2 transformed. Expression counts
were then normalized using the nSolver 4.0 software and custom
scripts in R 3.6.1.
Immunohistochemistry. Hematoxylin and eosin (H/E) staining was
performed to confirm the presence of invasive tumour cells (10%)
and determine the minimum tumour surface area (4 mm2). Proges-
terone receptor (PR) expression was identified using the 1E2 rabbit
monoclonal primary antibody (Ventana Medical Systems). PR-nega-
tive disease was defined as less than 1% of positive tumour cells.
Genomic analysis on MCF7 cell line. Microarray-based gene expres-
sion data was obtained from GEO GSE119552 (available at: https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119552). In the
original study, MCF7 breast cancer cell line was cultured for at least
24 h in steroid- and serum-deprived DMEM without phenol red and
with 1.5% charcoal/dextran-stripped FBS (Biowest). Cells were
treated for 24h with solvent as a control or 109 M E2. RNA was
extracted and gene expression analysis was performed using Agilent
SurePrint G3 Human GE v2 8 £ 60 microarrays [15].
Statistical analysis. To identify genes whose expression was signifi-
cantly different between paired samples (i.e., baseline versus after
treatment) or unpaired samples (i.e., different MCF-7 cell lines
treated with control or E2) we used a two-class paired or a multiclass
Significance Analysis of Microarray (SAM), respectively, with a false
discovery rate (FDR)<5% [16]. The SAM provides for each gene ana-
lyzed the standardized mean difference between the gene’s expres-
sion in a class (e.g., a cell line, a patient cohort etc.), versus its overall
mean expression in the dataset. The algorithm applies a t-test at the
individual gene level to determine whether the expression pattern
for that gene is significant and is able to identify up/down-regulated
genes by determining the deviations between observed and expected
relative differences, considering a prespecified cut-off for the FDR.
This is the rate at which a gene will be incorrectly identified as signif-
icant [16]. Paired or unpaired Student’s t test, Mann-Whitney test
and ANOVA were conducted whenever appropriate to compare con-
tinuous variables between groups. Univariate logistic regression was
performed to evaluate the association between PR expression accord-
ing to menopausal status in the HER2-negative HCB chemo-treated
cohort. All statistical tests were two-sided, and the statistical signifi-
cance level was set to <0.05. All analyses were performed using R
software version 4.0.2.
2.2. Role of funding source
The funders had no role in study design, data collection, data anal-
yses, interpretation, or writing of this report. All authors had full
access to all the data in the study and had final responsibility for the
decision to submit for publication.
3. Results
First, we analyzed tumour samples from the SOLTI-CORALLEEN
phase II clinical trial [11]. 106 post-menopausal patients with newly
diagnosed stage II-III hormone-dependent luminal B breast cancers
were randomized to either standard neoadjuvant anthracycline/tax-
ane-based chemotherapy or endocrine therapy (ET) of letrozole in
combination with ribociclib, a CDK4/6 inhibitor, for 6 months
(Fig 1a). We performed gene expression profiling of 771 breast can-
cer-related genes in pretreatment tumours, and in residual tumours
at surgery, using the nCounter platform (Nanostring Technologies,Seattle, USA). Within each arm, a gene list of the top-100 downregu-
lated genes by each therapy was obtained using a two-class paired
SAM. When we compared both gene lists, 81 of 100 genes (81%) were
common in both treatment arms including many proliferation-
related genes (e.g., MKI67, TOP2A and EXO1). A total of 19 genes were
found downregulated in the ET-based arm-only (Fig 1b), including
known oestrogen-regulated genes such as progesterone receptor
(PGR) [17], cyclin D1 (CCND1) [18], the trefoil factor 1 (TFF1) [19],
TFF3 [20], proliferating cell nuclear antigen (PCNA) and E2F transcrip-
tion factor 1 (E2F1) [21]. Of note, PGR, TFF1 and TFF3 have been previ-
ously correlated with plasma estradiol levels in HR+ breast cancer in
post-menopausal women [22].
To confirm these results, we first evaluated the expression of the
19 oestrogen-regulated genes using the nCounter platform in an
independent dataset of 20 post-menopausal patients with newly
diagnosed HR+/HER2-negative breast cancer (80% Luminal A, 15%
Luminal B and 5% normal-like) treated for 3 weeks with letrozole
monotherapy in the SOLTI-VENTANA clinical trial (Fig 1c-d) [12]. As
expected, all genes, including PGR (Fig 1e), were found significantly
downregulated in the post-treatment samples (Fig 1d). Secondly,
MCF7 ER+/HER2-negative cell line treated in vitro with 109 M estra-
diol (E2) showed a general up-regulation of the 19-gene signature,
including PGR, which showed a 6.1-fold up-regulation (Fig 1f). Finally,
PGR was also found down-regulated by 2 weeks of anti-oestrogen
therapy (i.e., tamoxifen or letrozole) in combination with anti-HER2-
based therapy (i.e. trastuzumab plus lapatinib) in pre-menopausal
and post-menopausal patients with HR+/HER2+/Luminal A or B
early-stage breast cancer in the PAMELA phase II clinical trial [13]. In
contrast, anti-HER2 therapy alone for 2 weeks did not decrease
PGR expression but conversely increased its expression in HR-
negative/HER2+ early-stage breast cancer, consistent with our
previous study showing that anti-HER2 therapy induces a luminal
phenotype [23].
Our previous results identified 19 oestrogen-regulated genes in
HR+ breast cancer. To evaluate the oestrogen signaling pathway dur-
ing chemotherapy, we analyzed tumour samples from the phase II
neoadjuvant SOLTI-NEOERIBULIN trial [14], in which 83 patients (35
pre-menopausal and 48 post-menopausal) with newly diagnosed HR
+/HER2-negative breast cancer (40% Luminal A, 39% Luminal B, 11%
normal-like, 8% Basal-like and 2% HER2-enriched) received 4 cycles
(i.e., 12 weeks) of eribulin in monotherapy, an anti-microtubule agent
(Fig 2a). We performed gene expression profiling of pretreatment
and residual tumours at surgery using the nCounter platform. Strik-
ingly, PGR was found significantly downregulated only in pre-meno-
pausal patients (Fig 2b). We observed similar findings with the other
19 oestrogen-regulated genes (Fig 2c). Conversely, no oestrogen-reg-
ulated gene was found differentialy expressed in 55 patients (12 pre-
menoapusal and 33 post-menopausal) with triple-negative breast
cancer in the SOLTI-NEOERIBULIN according to menopausal status
(data not shown). This result provided direct evidence that chemo-
therapy induces an anti-oestrogen effect in hormone-dependent
tumour cells in pre-menopausal patients. Interestingly, 80% (4 of 5)
of the pre-menopausal patients with HR+/HER2-negative breast can-
cer and age <40 had a 3-fold decrease of PGR compared to 23.3% (7 of
30) pre-menopausal patients with age 40 (p=0.026).
Progesterone receptor (PR) has been identified as a marker of oes-
trogenicity in numerous studies spanning 3 decades [22,24]. To fur-
ther explore the modulation of PR by chemotherapy in residual
tumours according to menopausal status, we evaluated the protein
levels by immunohistochemistry in an independent dataset of the 40
patients (13 pre-menopausal and 27 post-menopausal) with newly
diagnosed ER+/PR+/HER2-negative breast cancer treated with neoad-
juvant anthracycline/taxane-based chemotherapy at the HCB
(Fig 2d). The proportion of PR-negative disease in residual tumours at
surgery was 9 of 13 (69.2%) in pre-menopausal patients and 4 of 27
(14.8%) in post-menopausal patients (odds ratio=4.70; p-
Fig. 1. Identification of oestrogen-regulated genes in early-stage breast cancer
Legend and captions. (a) Schematic trial design and tumour samples from 99 patients with HR+/HER2-negative disease recruited in the SOLTI-CORALLEEN trial phase II clinical
trial(11). (b) Overlap of downregulated genes in SOLTI-CORALLEEN trial between both treatment arms (i.e., anthracycline/taxane [AT]-based chemotherapy and
letrozole + ribociclib), and identification of 19 genes found downregulated in the endocrine therapy (ET)-based arm- only. (c) Schematic trial design and tumour samples from the
SOLTI-VENTANA phase II clinical trial(12). (d) Unsupervised hierarchical clustering of 19 oestrogen-regulated genes using 20 paired ER+/HER2-negative (i.e., baseline and after 3-
weeks of letrozole) from the SOLTI-VENTANA trial(12). Heatmap shows high (red) / low (green) expression of mRNA for each sample and gene. (e) Progesterone receptor (PGR)
mRNA expression changes between baseline and after 3-weeks of letrozole monotherapy across 20 patients recruited in the SOLTI-VENTANA trial(12). Each line represents a patient.
Increases are represented in red and decreases in green. P-value (P) was determined using a two-tailed paired Students t-test. (f) Expression of the 19 oestrogen-regulated genes in
the MCF7 HR+/HER2-negative cell line treated with 109 M E2 versus control. Gene expression data was obtained from GEO GSE119552 (available at: https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE119552). (f) Schematic trial design and tumour samples from 108 patients with HER2+ early breast cancer, including HER2+/HR- (n=71) and HER2
+/HR+/Luminal A or B (n=37) disease recruited in the PAMELA phase II clinical trial(13). (h) Progesterone receptor (PGR) mRNA relative changes after 2 weeks of treatment in pre-
menopausal and post-menopausal patients. P-value (P) was determined one-way ANOVA with Tukey’s multiple comparisons test. ***: p<0.001; n/s: non-significant.
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decreased PR expression at residual tumours among pre-menopausal
patients treated with neoadjuvant chemotherapy, but not post-men-
opausal patients [25]. Finally, we explored the ability of chemother-
apy to reduce the levels of PGR in 73 pre-menopausal and post-
menopausal patients with HER2+ early-stage breast treated with
neoadjuvant anti-HER2-based multi-agent chemotherapy at the HCB
(Fig 2e). Consistent with previous findings, a mean decrease in PGRlevels was only observed in pre-menopausal patients with HR+/HER2
+ disease (Fig 2f).
4. Discussion
To our knowledge, this is the first report to provide biological evi-
dence that the benefit of chemotherapy in pre-menopausal patients
with a newly diagnosed oestrogen-dependent breast cancer is likely
Fig. 2. Oestrogen-regulated genes following chemotherapy in early-stage breast cancer permenopausal status
Legend and captions. (a). Schematic trial design and tumour samples from the SOLTI-NEOERIBULIN phase II clinical trial(14). (b) Progesterone receptor (PGR) mRNA expression
changes between baseline and after 4 cycles of eribulin monotherapy in 83 patients with residual tumours at surgery (i.e., 35 pre-menopausal and 53 post-menopausal). Each line
represents a patient. Increases are represented in red and decreases in green. P- value (P) were determined using a two-tailed paired Students t-test. (c). Changes in gene expression
after 4 cycles of eribulin in 83 patients included in the SOLTI-NEOERIBULIN trial permenopausal status. Heatmap shows high (red) / low (green) expression of mRNA. (d) Images and
summary of progesterone receptor (PR) status by immunohistochemistry in residual tumours of 40 patients (13 pre-menopausal and 27 post- menopausal) with PR+/HER2-negative
breast cancer treated with anthracycline/taxane- based neoadjuvant chemotherapy at the Hospital Clinic of Barcelona (Hematoxylin and eosin staining, original magnification x10).
(e) Schematic trial design and tumour samples from 73 HER2+ early-stage breast patients treated with neoadjuvant anti-HER2-based multi-agent chemotherapy for 4-6 months,
including HER2+/HR- (n=20) and HER2+/HR+/Luminal A or B (n=53) (f) Progesterone receptor (PGR) mRNA relative changes after 4-6 months of treatment in pre-menopausal and
post-menopausal patients P-value (P) was determined using a two-tailed unpaired Mann-Whitney test. **: p<0.01.
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therapy. This effect is similar to the anti-oestrogen effect induced by
an aromatase inhibitor in post-menopausal patients, where oestro-
gen biosynthesis is suppressed in peripheral tissues through the inhi-
bition of the aromatization of androgens to oestrogens [8]. However,
differently from what occurs in menopause, the predominant sourceof oestrogens in pre-menopausal women is the ovary. Thus, the most
likely explanation of our findings is that chemotherapy induces ovar-
ian function suppression in pre-menopausal patients, leading to
lower systemic levels of estradiol, which then causes reduced expres-
sion of oestrogen/oestrogen-receptor regulated genes in tumour
cells. Our findings could explain, in part or in total, the recent clinical
6 N. Chic et al. / EBioMedicine 69 (2021) 103451findings from TailorX [3], MINDACT [4] and RxPONDER [5] random-
ized trials in >10,000 patients with HR+/HER2-negative breast cancer
with a genomic low-risk by OncotypeDX or MammaPrint, which are
biomarkers largely tracking tumour cell proliferation. In these stud-
ies, unlike post-menopausal patients, pre-menopausal patients
obtained survival benefit from adjuvant chemotherapy. This survival
benefit of chemotherapy was also observed in pre-menopausal
patients with very low proliferation status (i.e., recurrence score of 0-
14 by OncotypeDX in RxPONDER) [5]. Of note, the proportion of
patients receiving luteinizing hormone-releasing hormone (LHRH)
analogues in these trials was less than 20% [35]. These results rein-
force our hypothesis that the benefit induced by chemotherapy in
pre-menopausal women is directly related to its ability to induce
ovarian function suppression.
Our study present some limitations that need to be acknowl-
edged. Firstly, this is a retrospective and exploratory analyses from
available datasets, with all the known limitations and biases concern-
ing sample and dataset availability. Secondly, we had no data regard-
ing patients’ oestradiol (E2), FSH and LH blood levels. Consequently,
we could not assess any direct correlation between ovarian function
and the molecular findings. Finally, the different patients cohorts pro-
ceeded from different prospective interventional and observational
multicentre clinical trials, being thus prone to a selection bias. In this
regard, it would be useful to expand on the results of the present
study by performing confirmatory analyses on tissues from a broader
number of patients in wider randomized trials [2631]. Nonetheless,
results are consistent between similar cohorts and cell lines assays
and provide a coherent explanation of the clinical results observed in
TailorX [3], MINDACT [4] and RxPONDER [5] trials.
In summary, we have shown that chemotherapy (i.e., eribulin or
anthracycline/taxane-based chemotherapy) exerts an anti-oestro-
genic biological effect on tumour samples from pre-menopausal
patients, which is very similar to that observed with aromatase inhib-
itors on tumour samples from post-menopausal women. Our chemo-
induced endocrine signature, not previously reported, to our knowl-
edge, strongly supports the lengthily accepted hypothesis that at
least a substantial proportion of the survival gain obtained from che-
motherapy in pre-menopausal women is due to an endocrine effect,
most likely via a decrease in global estradiol levels secondary to ovar-
ian function suppression[10, 32]. This is in line with results of several
phase 3 trials and one subsequent meta-analysis showing similar
outcomes for adjuvant LHRH analogue treatment, alone or added to
chemotherapy, versus chemotherapy for all pre-menopausal popula-
tion with ER+ breast cancer [33]. Interestingly, survival benefits with
the addition of LHRH analogues to chemotherapy were only seen in
younger women (<40 years), precisely those with lower probability
of definitive chemo-induced amenorrhea [33]. Indeed, a non-mean-
ingless proportion of women experience recovery of estradiol and
FSH levels to pre-menopausal range in the subsequent months[34,
35]. In this context, pivotal phase 3 trials such as SOFT, TEXT and AST-
TRA have established the superiority of adding ovarian function sup-
pression to an aromatase inhibitor/tamoxifen versus tamoxifen alone
in pre-menopausal women with HR+ early- stage breast cancer [35,
36]. However, whether LHRH analogues can be used to substitute the
endocrine effects of chemotherapy and obtain similar survival out-
comes is currently unknown. Nonetheless, our translational study
gives consistency to this hypothesis. Finally, a large phase III clinical
trial with survival outcome as the primary endpoint is likely needed
to demonstrate the endocrine effects of chemotherapy in pre-meno-
pausal patients. This trial could randomize pre-menopausal patients
with early-stage HR+/HER2-negative breast cancer to chemotherapy
versus no chemotherapy, where all patients are subjected to ovarian
function suppression.
To conclude, despite some limitations, our results proffer a strong
rationale to develop and/or test effective and more targeted anti-oes-
trogen treatment strategies in pre-menopausal patients. For example,LHRH modulators could be evaluated to decrease or avoid the use of
systemic chemotherapy in hormone-dependent breast cancer. In this
context, the capacity of each treatment strategy, including different
LHRH modulators and schedules, to afffect ovarian and ER function
might be of critical importance [8,37]. For instance, LHRH modulators
such as degarelix (i.e., a potent LHRH antagonist) achieves a faster
ovarian function suppression, which is more effectively maintained
compared to triptorelin (i.e., a LHRH agonist) [38]; thus, the magni-
tude of ovarian function suppression might be important [8,37].
Another relevant aspect to consider is the existence of a direct cyto-
toxic effect of chemotherapy on tumour cells, which is likely to be
related to their proliferative status (i.e., more tumour proliferation,
more benefit from chemotherapy). Future trials in pre-menopausal
early-stage hormone-dependent breast cancer to de-escalate and/or
escalate systemic therapy should be designed with these results in
mind, including hormone-dependent HER2+ breast cancer.
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